恩度联合化疗药物治疗晚期非小细胞肺癌疗效观察

目的观察恩度联合化疗药物在晚期非小细胞肺癌中的治疗效果,并进行评估。方法选择本院就诊的78例晚期NSCLC患者,分别接受三种不同的化疗药物治疗,A组患者使用紫杉醇＋卡铂＋恩度组合治疗,B组患者使用多烯紫杉醇＋卡铂＋恩度组合治疗,C组患者使用长春瑞滨＋卡铂＋恩度组合治疗。对三组治疗效果、生存质量改变以及毒副作用进行统计对比。结果所有78例患者完成两个周期化疗后评定疗效,其中A组患者临床治疗有效率为34.6%,B组患者临床治疗有效率为21.7%,C组患者临床治疗有效率为44.8%。C组与B组对比差异有统计学意义,C组生活质量明显改善,三组毒副作用对比均有统计学意义。结论恩度联合长春瑞滨及顺铂治疗晚期NSCLC效果显著,并无明显的毒副反应,能很好的改善患者的生存质量,值得临床进一步推广。

Effect of endostatin combined with chemotherapy in the treatment of advanced non-small cell lung cancer

Objective To evaluate the effect and safety of endostatin combined with chemotherapy in the treatment of advanced non-small cell lung cancer.Methods 78 patients with advanced NSCLC were treated with three different chemotherapy drugs,A group: paclitaxel + cisplatin + endostatin,B group: docetaxel+cisplatin+ endostatin,C group: vinorelbine+cisplatin+ endostatin.The treatment effect,quality of life changes and side effects were compared among three groups.Results All the patients completed 2 cycles of chemotherapy.Clinical effective rates of group A,B,C were 34.6%,21.7% and 44.8%,respectively,and there were significant difference between group B and group C;life quality significantly improved in group C;there were no statistically different of side effects in three groups.Conclusion Endostatin combined spring vinorelbine and cisplatin is effective to treat advanced NSCLC,with improving life quality and no obvious side effects.